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Abstract
microRNA-132 (miR-132) is involved in prosurvival, anti-inflamma-
tory and memory-promoting functions in the nervous system and
has been found consistently downregulated in Alzheimer’s disease
(AD). Whether and how miR-132 deficiency impacts AD pathology
remains, however, unaddressed. We show here that miR-132 loss
exacerbates both amyloid and TAU pathology via inositol 1,4,5-
trisphosphate 3-kinase B (ITPKB) upregulation in an AD mouse
model. This leads to increased ERK1/2 and BACE1 activity and
elevated TAU phosphorylation. We confirm downregulation of miR-
132 and upregulation of ITPKB in three distinct human AD patient
cohorts, indicating the pathological relevance of this pathway in AD.
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Introduction
The pathogenic process in Alzheimer’s disease (AD) involves a long
cellular phase during which intricate feedback and feed-forward
cascades between distinct cell types affect the homeostasis of the
brain. This progressively leads to the clinical stage of the disease (De
Strooper & Karran, 2016). MicroRNAs (miRNAs) keep the expression
of various genes in check and are typically part of molecular home-
ostasis mechanisms. While the expression of miRNAs is disturbed in
AD brain (He´bert et al, 2008; Lau et al, 2013), it remains largely
unknown how these aberrations are induced and whether they play a
role in disease progression (Salta & De Strooper, 2012). Even if the
disruption of miRNA expression is part of the general pathogenic
process induced by accumulating toxic cues, it remains important to
investigate whether loss or gain of function of particular miRNAs has
also a specific functional impact on AD pathology. miRNAs that are
systematically and early downregulated in the disease course are of
particular interest in that regard. MicroRNA-132 (miR-132) is one of
the few miRNAs that are consistently and robustly downregulated in
AD brain (Cogswell et al, 2008; Hebert et al, 2013; Lau et al, 2013;
Wong et al, 2013; Smith et al, 2015), suggesting a functional involve-
ment in the pathogenic process. miR-132 has neuroprotective proper-
ties regulating the prosurvival PI3K-AKT pathway, which represses a
death signaling cascade that involves FOXO3a, P300, and PTEN in
primary hippocampal and cortical neurons (Wong et al, 2013). More-
over, miR-132 expression levels are negatively correlated to hyper-
phosphorylated TAU aggregates in the cortex of AD patients (Lau
et al, 2013) and miR-132 knockout increases TAU phosphorylation
and aggregation in a triple transgenic AD mouse model (Smith et al,
2015). Notably, miR-132 deficiency in AD brain might have addi-
tional neurotoxic effects as miR-132 is involved in neuronal plasticity
and synaptic function (Edbauer et al, 2010; Bicker et al, 2014; Salta
et al, 2014), it has been implicated in neuroinflammation and the
regulation of acetylcholinesterase expression (Shaked et al, 2009),
while activity-induced CREB-dependent miR-132 transcription also
contributes to memory formation and cognition (Hansen et al, 2013).
Overall these observations suggest that loss of miR-132 could play a
pivotal role in several aspects of AD. However, to date, little hard
data are available providing factual support to the hypothesis that
miR-132 is part of the disease process.
In this study, we set out to characterize the functional impact of
miR-132 deficiency on AD pathology in brain and to begin to dissect
the molecular networks underlying these effects. We demonstrate
here that downregulation of miR-132 aggravates both amyloid and
TAU pathology in AD mice and that it regulates the expression of
inositol 1,4,5-trisphosphate 3-kinase B (ITPKB), a regulator of
BACE1 activity and TAU phosphorylation (Stygelbout et al, 2014).
We suggest that loss of miR-132 is part of a feed forward loop
enhancing the biochemical stress that drives the disease.
Results
In vivo manipulation of miR-132 levels in the hippocampus of
APPPS1 mice
We previously observed miR-132 downregulation at Braak stage III in
AD brain (Lau et al, 2013), suggesting a relatively early role of this
miRNA in the disease process. To assess this further, we downregu-
lated miR-132 using intracerebroventricular (ICV) injections of locked
nucleic acid (LNA)-modified, 30 cholesterol-conjugated antisense
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Figure 1. Efficiency and specificity of in vivo down- and upregulation of miR-132.
A Experimental scheme of antagomiR-132 and miR-132 mimic injections into the lateral ventricle of 2-month-old APPPS1 mice.
B Semi-quantitative PCR of miR-132 and negative control miRNAs in the hippocampus of antagomiR-132-injected mice (ant-132) in comparison with control-injected
animals (aCSF and scramble) at 6 months of age. Sample size, n = 9 per group.
C FISH of miR-132 and negative control miR-124 in the hippocampus of ant-132- and scramble-injected mice. Scramble probes were used as FISH negative controls.
Scale bar, 500 lm.
D Semi-quantitative PCR of miR-132 and miR-212 in the hippocampus of 3-month old miR-132 mimic-injected mice (miR-132) compared to animals injected with a
negative control oligonucleotide (Ctr). Sample size, n = 6 per group.
Data information: Values were normalized to scramble- (B) or control-injected group (D) and presented as mean  SEM. In (B), one-way ANOVA was used, while in (D),
Student’s t-test was applied.
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antagomiR-132 oligonucleotides in 2-month-old APPPS1 mice. These
mice co-express human-mutated APPSwe (KM670/671NL APP) and
human-mutated presenilin 1 (L166P) (Fig 1A). This widely used AD
model [Tg(Thy1-APPSw, Thy1-PSEN1*L166P) 21Jckr] typically
shows amyloid deposition in the hippocampus at 3–4 months and
cognitive impairment at 7–8 months of age (Radde et al, 2006;
Serneels et al, 2009). Monthly ICV injections of antagomiR-132
resulted in an approximately 80% decrease of miR-132 levels at
6 months of age (Fig 1B and C). A miR-132 scramble oligonucleotide
did not have any effect on miR-132 expression, similarly to injections
with only artificial cerebrospinal fluid (aCSF) used as carrier. No
changes in the expression of miR-212—a miRNA transcribed in the
same cluster as miR-132—or of three other, unrelated miRNAs, that is
miR-127, miR-29b (Fig 1B), and miR-124 (Fig 1C), were observed.
We additionally performed overexpression experiments using double-
stranded miR-132 mimic oligonucleotides. Four ICV injections of
150 pmol miR-132 mimic with one-week interval led to a 15-fold
upregulation of miR-132 in hippocampus at 3 months of age, again
without affecting the levels of the closely related miR-212 (Fig 1D).
miR-132 regulates soluble and insoluble Ab
We assessed the levels of Ab after up- or downregulation of miR-132.
Amyloid immunostaining in the ant-132-injected animals revealed a
twofold and a 1.7-fold increase of plaque burden in hippocampus and
cortex, respectively (Fig 2A and B). We next used ELISA to measure
hippocampal Ab40 and Ab42 levels. Both peptides were significantly




Figure 2. Effect of miR-132 on Ab accumulation.
A Amyloid staining (6E10) combined with miR-132 FISH in ant-132- and scramble-injected mice at 6 months of age. Scale bar, 500 lm.
B Quantification of amyloid burden in hippocampus and cortex of ant-132-injected and control animals (see Materials and Methods). Sample size, n = 4 per group.
C, D ELISA of soluble (TBS) and insoluble (Formic acid) Ab40 and Ab42 levels in the hippocampus of ant-132- (C) and miR-132-injected (D) animals at 6 and 3 months of
age, respectively. Sample size, n = 6 per group.
Data information: In (B–D) values were normalized to scramble- (B, C) or control-injected group (D) and presented as mean  SEM. Student’s t-test was used.
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formic acid-soluble fractions in response to miR-132 downregulation
(Fig 2C). In contrast, a significant decrease of soluble and insoluble
Ab40 and Ab42 was observed upon miR-132 ectopic expression in
hippocampus (Fig 2D). These data indicate an inhibitory effect of
miR-132 over soluble and aggregated Ab species formation.
miR-132 controls TAU phosphorylation
Among the most prominent kinases involved in TAU hyperphosphory-
lation in AD are ERK1/2, CDK5, and GSK3B (Mandelkow et al, 1995),
and in silico analysis (Targetscan 7.0) predicts ERK1, ERK2, GSK3b,
and TAU itself as putative miR-132 targets in human and mouse. Total
TAU levels were, however, not affected following miR-132 down- or
upregulation (Fig 3A and B top panel) contrary to a previous report
(Smith et al, 2015). TAU phosphorylation levels were, in contrast,
significantly altered in antagomiR-132- or miR-132 mimic-injected
mice as assessed by Western blot using antibody AT8 against phos-
phorylated Ser-202/Thr-205 and antibody AT270 against phosphory-
lated Thr-181 (Mandelkow & Mandelkow, 2012) (Fig 3A and B middle
and bottom panels). These two epitopes can be phosphorylated by
ERK1/2, CDK5, and GSK3b (Fig EV1). However, no change in the
expression levels of these kinases was observed upon miR-132 down-
regulation in APPPS1 hippocampus (Fig EV2). We further assessed
the phosphorylation of two additional sites in TAU, which are phos-
phorylated by CDK5 and GSK3B but not by ERK1/2, namely Thr-212/
Ser-214 (recognized by antibody AT100) and Thr-231 (recognized by
antibody AT180) (Mandelkow & Mandelkow, 2012; Fig EV1). Interest-
ingly, phosphorylation levels of these epitopes were unaffected by
miR-132 ectopic expression, which, together with the positive AT8/
AT270 staining, suggested that ERK1/2 might be part of the kinases
involved in the miR-132-mediated effect on TAU phosphorylation.
miR-132 target identification
While the previous experiments demonstrate that miR-132 down-
regulation increases Ab generation and TAU phosphorylation, the
targets mediating these effects remain unknown. In a first approach
to make a choice among the 1,332 predicted miR-132 targets
conserved among human and mouse (Targetscan 7.0), we made use
of data previously obtained in six healthy (Braak stage 0-I) and six
diseased human AD (Braak stage V-VI) prefrontal cortex (PFC)
samples. We quantified the levels of miR-132 in the different brains
using the next generation RNA sequencing dataset published in Lau
et al (2013) and the levels of the different candidate mRNAs as
deduced from the microarray transcriptome study performed on the
same samples (Bossers et al, 2010) and correlated miR-132 expres-
sion and predicted miR-132 target levels (Fig 4A) (see Materials and
Methods). This approach yielded a list of 19 predictedmiR-132 targets
whose expression is significantly upregulated and anticorrelated with
miR-132 levels in AD (Table 1). We then assessed with real-time PCR
A B
Figure 3. Regulatory effect of miR-132 on TAU expression and phosphorylation.
A, B Western blot analysis of total TAU and pTAU (AT8, AT270) levels upon miR-132 knockdown (A) or overexpression (B) at 6 and 3 months of age, respectively. Sample
size, n = 9 per group (A) and n = 6 per group (B). Values were normalized to the respective control groups and presented as mean  SEM. Student’s t-test was used.
Source data are available online for this figure.
EMBO Molecular Medicine Vol 8 | No 9 | 2016 ª 2016 The Authors
EMBO Molecular Medicine miR-132 ameliorates Ab and TAU pathology in AD Evgenia Salta et al
1008
Published online: August 1, 2016 
which of these transcripts additionally became upregulated in the
APPPS1 mice upon miR-132 downregulation (Fig 4B). We set as
threshold a 1.3-fold change above baseline levels (Selbach et al,
2008) and found five mRNAs that responded to that criterion: Taf4,
Arid1A, Erbb2ip, ItpkB, and Kccn3. A search in PubMed using as
keywords each transcript’s name in combination with Alzheimer,
amyloid, Abeta, or TAU yielded no results for Taf4, Arid1A, Erbb2ip,
and Kcnn3. However, strikingly, one of these candidates, the inositol
1,4,5-trisphosphate 3-kinase B (ITPKB), was recently shown to
induce both Ab aggregation and TAU phosphorylation in 5XFADmice
(APP K670N/M671L (Swedish) + I716V (Florida) + V717I (London),
and PS1 M146L + L286V) (Stygelbout et al, 2014). Since such a target
would theoretically explain the observed impact of miR-132 defi-
ciency on Ab and pTAU in APPPS1 mice, we set out to further explore
the possible regulatory interplay between miR-132 and ITPKB.
The miR-132 target ITPKB mediates miR-132 effects on Ab
The 30UTR of ITPKB contains one predicted miR-132 binding site
conserved among human and mouse and an additional one which is
unique to human ITPKB. We used a luciferase reporter construct
containing the human ITPKB 30UTR to co-transfect HEK293 cells along
with a miR-132 mimic or a negative control oligonucleotide. Co-
transfection with the miR-132 mimic led to an approximate
luminescence repression of 70% compared to the negative control-
transfected cells (Fig 5A). Mutating the two predicted miR-132 binding
sites in the 30UTR of ITPKB completely abolished the effect on
luciferase enzymatic activity (Fig 5A), indicating that ITPKB is a direct
miR-132 target in vitro. Since ITPKB has been shown to affect Ab
generation (Stygelbout et al, 2014), we assessed whether ITPKB is
necessary and/or sufficient to induce the effect of miR-132 on Ab
levels. Transfection of HEK293 cells overexpressing human APPSwe
with a miR-132 antisense oligonucleotide led to a significant increase
of both Ab40 and Ab42 confirming our in vivo findings (Fig 5B). Inter-
estingly, downregulation of ITPKB using an siRNA oligonucleotide
resulted in a reduction of Ab levels pointing toward the pro-amyloido-
genic role of ITPKB (Fig 5B). Moreover, simultaneous downregulation
of ITPKB rescued the miR-132 knock down effect on Ab levels
(Fig 5B). Knockdown efficiency of miR-132 and ITPKB is shown in
Fig EV3. We then assessed whether altering ITPKB levels was suffi-
cient to exert an effect on Ab levels in vivo. Indeed, downregulation of
ITPKB using ICV injections of an ITPKB siRNA resulted in significantly
decreased insoluble Ab levels in APPPS1 hippocampus (Fig 5C and
D), a finding that mimics the effects observed upon miR-132 overex-
pression and indicates the possible functional involvement of ITPKB
in the miR-132-dependent effect on Ab. Finally, to dissect the in vivo
regulatory relationship between miR-132 and ITPKB, we assessed
ITPKB expression in the hippocampus of antagomiR-132- and miR-132
mimic-injected APPPS1 mice. ITPKB was significantly upregulated
following miR-132 downregulation (Fig 5E), while miR-132 overex-
pression significantly repressed ITPKB levels (Fig 5F) indicating that,
also in vivo, ITPKB is under the regulatory control of miR-132.
miR-132 regulates ERK1/2 and BACE1 enzymatic activity
It has been previously shown that ITPKB has a dual regulatory role
in relation to AD pathology: It can affect BACE1 activity leading to
more Ab generation, while at the same time, it promotes TAU
phosphorylation via phosphorylation and activation of ERK1/2
(Stygelbout et al, 2014). No differences between antagomiR-
132- and control-injected mice were observed with regard to total
APP and BACE1 levels (Fig EV4). Interestingly, APP CTFb and
soluble APPb (sAPPb), the two products derived from the prote-
olytic processing of APP by BACE1, were indeed elevated upon
miR-132 downregulation in the hippocampus of the APPPS1 mice,
while a significant decline was observed upon miR-132 upregulation
(Fig 6A and B), indicating that miR-132 negatively regulates BACE1
activity. Moreover, increased levels of phosphorylated ERK1/2 were
observed in the antagomiR-132-injected mice, while reversely,
phosphorylation of ERK1/2 decreased in the miR-132 mimic-injected
A
B
Figure 4. miR-132 target screening and validation.
A Correlation analysis process: miRNA and mRNA profiling datasets were cross-
checked for miR-132 predicted targets that are significantly anticorrelated to
miR-132 expression and significantly upregulated at late stages of AD.
B Positive hits were validated by semi-quantitative qPCR in ant-132-injected
mouse hippocampus. Black line indicates mean of scramble control set to 1.
Dashed line indicates chosen threshold of 1.3-fold. Sample size, n = 9 per
group. Values were normalized to scramble-injected group and presented
as mean  SEM.
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APPPS1 hippocampus (Fig 6C), suggesting that miR-132 acts
upstream of ITPKB in a cascade eventually regulating ERK1/2
phosphorylation.
ITPKB colocalizes with amyloid plaques and neurofibrillary
tangles in human AD brain and exhibits a mutually exclusive
expression pattern to miR-132
We further validated miR-132 levels in an independent set of human
AD prefrontal cortex samples. miR-132 was approximately twofold
downregulated in AD compared to non-demented control samples
in agreement with previous work (Lau et al, 2013; Fig EV5). miR-
124 was previously reported not to change in human AD prefrontal
cortex (Lau et al, 2013) and was therefore used as negative control.
Interestingly, ITPKB colocalized with amyloid plaques (Fig 7A). We
then assessed the in situ expression patterns of miR-132 and ITPKB
in neurons bearing NFTs in AD prefrontal cortex (Fig 7B and C).
Low miR-132 expression was observed in cells displaying ITPKB
and pTAU accumulation, while miR-132 signal was high in cells
with lower ITPKB+- and pTAU+-immunolabeling. This was not
observed for miR-124 expression. ITPKB levels were elevated in
cells with strong pTAU immunoreactivity.
The miR-132/ITPKB pathway is disrupted in human AD brain
We finally assessed the expression of the different molecular players
in 39 late-stage AD and 15 control hippocampal samples. These
brains were part of the patient cohorts in which we originally
reported the downregulation of miR-132 (Lau et al, 2013). We con-
firmed miR-132 deficiency in these samples by real-time PCR
(Fig 8). Interestingly, along elevated phosphorylated ERK1/2 and
phosphorylated TAU levels, we also observed significantly increased
ITPKB expression (Fig 8). Notably, ITPKB levels were significantly
correlated to phosphorylated TAU (AT270) levels (Pearson’s
r = 0.7; P = 0.002). No changes in total ERK1/2 or TAU expression
were observed.
Discussion
We show here that loss of miR-132 in the context of an AD mouse
model affects the two arms of the biochemical cascade that leads to
the well-known AD pathology. miR-132 knockdown in APPPS1 mice
increases soluble and insoluble Ab and amyloid burden, while it
also enhances TAU phosphorylation in hippocampus. These effects
are reversed upon miR-132 overexpression, suggesting a direct rela-
tion between miR-132 levels and these biochemical phenotypes.
Thus, the strong miR-132 downregulation previously observed in
AD brain is not only a consequence of the disease process but also
contributes to the biochemical alterations that characterize the
pathology. The dual effect on Ab and TAU is surprising and is
apparently—partially—mediated by inositol 1,4,5-trisphosphate
3-kinase B or ITPKB. Interestingly, ITPKB mRNA and protein levels
increase up to threefold in human AD frontal cortex (Bossers et al,
2010; Saetre et al, 2011; Stygelbout et al, 2014). Here, we confirm
the significant ITPKB upregulation along with the strong miR-132
Table 1. Predicted miR-132 targets that were significantly upregulated and anticorrelated with miR-132 expression in human AD prefrontal cortex.
Transcript ID Pearson’s correlation Differential expression
Symbol NCBI ID r P-value BH adj P-value P-value BH adj P-value
KIAA1958 AB075838 0.878 0.0002 0.0175 6.3E-05 0.0142
ZBTB34 AB082524 0.857 0.0004 0.0285 2.8E-09 0.0001
ZCCHC11 NM_001009881 0.846 0.0005 0.0294 9.0E-05 0.0165
CAPN2 NM_001748 0.768 0.0036 0.0443 3.7E-04 0.0277
ITGB8 NM_002214 0.765 0.0038 0.0443 7.5E-05 0.0156
ITPKB NM_002221 0.766 0.0036 0.0443 2.4E-04 0.0233
KCNN3 NM_002249 0.814 0.0013 0.0362 1.1E-04 0.0186
SP3 NM_003111 0.765 0.0037 0.0443 1.0E-03 0.0443
TAF4 NM_003185 0.884 0.0001 0.0163 3.8E-06 0.0035
PRPF4B NM_003913 0.783 0.0026 0.0421 2.0E-04 0.0220
TJP2 NM_004817 0.731 0.0069 0.0555 1.2E-03 0.0478
NFIB NM_005596 0.764 0.0038 0.0443 7.3E-04 0.0386
ARID1A NM_006015 0.859 0.0003 0.0285 1.1E-04 0.0186
SIRT1 NM_012238 0.908 0.0000 0.0112 5.4E-07 0.0013
ZNF395 NM_018660 0.792 0.0021 0.0403 4.4E-04 0.0302
ERBB2IP NM_018695 0.784 0.0026 0.0420 3.6E-04 0.0276
PARD3 NM_019619 0.802 0.0017 0.0370 1.1E-04 0.0182
ARHGAP21 NM_020824 0.820 0.0011 0.0354 1.2E-04 0.0190
HSPA2 NM_021979 0.886 0.0001 0.0161 2.1E-05 0.0076
P-values were adjusted using the Benjamini–Hochberg correction. Differential expression data were deduced from Bossers et al (2010).
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downregulation in AD brain. Moreover, up- or downregulation of
miR-132 in mouse hippocampus led to a direct down- or upregula-
tion of ITPKB, respectively. Intriguingly, this kinase is known to
phosphorylate ERK1/2 (Wen et al, 2004; Mare´chal et al, 2007) lead-
ing to increased TAU phosphorylation and at the same time
enhanced BACE1 activity (and Ab accumulation) in another mouse
model of AD (Stygelbout et al, 2014). Along these lines, we report
that ITPKB deficiency in vivo results in a significant decrease in Ab
levels in AD mouse hippocampus. The direct link between miR-132
and ITPKB was further confirmed in a genetic occlusion experiment
in cell culture demonstrating that the effect of downregulation of
miR-132 on Ab generation is neutralized by downregulating ITPKB
at the same time (Fig 5B).
We and others previously suggested that miR-132 directly affects
TAU expression as MAPT mRNA contains a miR-132 binding site
(Lau et al, 2013; Smith et al, 2015). We could not demonstrate
such an effect here, although Smith et al (2015) recently reported
elevated mouse and human TAU expression in both wild-type and
triple transgenic (APPSwe/PSENM146V/TAUP301L, 3xTg-AD) mice
following genetic deletion of the miR-132/212 cluster. Obviously,
we induce here miR-132 knockdown in young adult mice, while
the genetic knockout is already present at birth, which could
explain this apparent discrepancy. It should be pointed out,
however, that in the latter model, the human TAU transgene does
not contain the MAPT 30UTR, and therefore, it is not clear how the






Figure 5. miR-132 regulation over ITPKB.
A Luciferase reporter assay of wild-type (wt) and mutant (mut) ITPKB 30UTR in HEK293 cells co-transfected with a synthetic miR-132 (miR-132) or a negative control
(Neg Ctr) oligonucleotide.
B ELISA of Ab40 and Ab42 levels in HEK293-APP
swe cells transfected with a miR-132 antisense oligonucleotide (miR-132 inh), an siRNA against ITPKB (ITPKB siRNA) or both.
C Western blot analysis of ITPKB knockdown in APPPS1 hippocampus using an siRNA oligonucleotide against ITPKB. Sample size, n = 6 per group. Values were
normalized to control-injected group (Ctr) and presented as mean  SEM.
D ELISA of insoluble (formic acid soluble) Ab40 and Ab42 levels in the hippocampus of ITPKB siRNA- and control-injected animals at 3 months of age. Sample size,
n = 6 per group. Values were normalized to control group and presented as mean  SEM.
E, F Western blot analysis of ITPKB levels upon miR-132 down (E)- or upregulation (F) at six and three months of age, respectively. Sample size, n = 9 per group for
miR-132 downregulation and n = 6 per group for miR-132 overexpression. Values were normalized to control groups and presented as mean  SEM.
Data information: The assays in (A and B) were performed in three independent experiments, each in triplicates. In (A, C–F) Student’s t-test was used, while in (B),
one-way ANOVA was employed.
Source data are available online for this figure.
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explained. Our data indicate that the endogenous TAU is not
directly affected by miR-132 regulation, but that, indirectly,
increased activity of ERK1/2, induced by ITPKB, could explain the
increased TAU phosphorylation.
The second AD-related effect of miR-132 downregulation, the
increase in Ab generation, is also—at least partially–mediated by
increased ITPKB levels. This effect has the signature of increased
BACE1 activity as APP CTFb and sAPPb were increased, as well.
A previous report had already indicated that ITPKB activates
BACE1 (Stygelbout et al, 2014). Interestingly, ERK1/2 has
previously been shown to affect membrane lipid composition
and thereby promote BACE1 enzymatic activity via phosphoryla-
tion of sphingosine kinase in neurons (Takasugi et al, 2011).
Further supporting the possible relevance of these observations
in human brain, we found increased levels of phosphorylated
sphingosine kinase in the AD hippocampi compared to the
controls (Fig 8).
The real novelty of our work stems from the insight that miR-132
is upstream of ITPKB, which links our previous observation of
miR-132 downregulation in AD to a pathologically relevant mecha-
nism. The link between miR-132 and ITPKB, ERK1/2 activity, APP
processing, Ab accumulation and TAU phosphorylation is strong
as shown by the consistent effects upon in vivo up- and downregula-
tion of miR-132 in the brain of an AD mouse model. We further
employed three independent sets of AD patient samples to explore
to which extent the proposed miR-132/ITPKB pathway may also
occur in AD brain. Notably, ITPKB significantly increased in late-
stage AD hippocampal samples, in which miR-132 levels were found
to be decreased by approximately 50%. Moreover, in the same set
of samples, we were able to confirm enhanced levels of activated
ERK1/2 (pERK1/2) and pTAU. ERK is required for TAU hyperphos-
phorylation in mice (Le Corre et al, 2006), while ERK1/2 activity,
but not total protein levels, was previously found to be elevated in
human AD brain (Ferrer et al, 2001) concomitantly with initial TAU
deposition, reflecting one of the earliest events in disease pathogen-
esis (Stygelbout et al, 2014). This is remarkably congruent with the
miR-132 downregulation at the early Braak stage III as previously
reported (Lau et al, 2013).
We report here that the well-established miR-132 loss in AD
brain has a presumably early, dual effect on key biochemical
aspects of pathogenesis: It aggravates both amyloid and TAU
pathology likely, and at least partially, via direct regulation of the
kinase ITPKB. This mechanism amplifies both pathologies. Strate-
gies to simultaneously tackle both amyloid and TAU pathways in
AD would possibly represent a highly efficient approach to halt
the pathogenic process. Therefore, and given the versatility and
the increasing know-how in using miRNAs as therapeutics, it is




Figure 6. Effect of miR-132 regulation on BACE1 and ERK1/2 activity.
A–C Western blot analysis of CTFb (A), sAPPb-swe (B) and phosphorylated ERK1/2 (pERK1/2) (C) levels upon miR-132 down (ant-132) (left panel)- or upregulation
(miR-132) (right panel) in APPPS1 hippocampus at 6 and 3 months of age, respectively. Sample size, n = 9 per group for miR-132 downregulation and n = 6 per
group for miR-132 overexpression. Values were normalized to respective control groups and presented as mean  SEM. Student’s t-test was used.
Source data are available online for this figure.
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AB
C
Figure 7. miR-132/ITPKB expression profile in human AD prefrontal cortex.
A Double immunofluorescence staining of amyloid plaques (6E10) and ITPKB in AD prefrontal cortex. Scale bar, 50 lm. Arrowheads indicate ITPKB immunopositivity.
B miR-132 FISH coupled with double immunofluorescence against hyperphosphorylated TAU (AT8)-containing neurofibrillary tangles (NFTs) and ITPKB in AD prefrontal
cortex. miR-124 was used as a control. Scale bar, 50 lm.
C Quantification of miR-132, ITPKB and hyperphosphorylated TAU (pTAU) signal in single neurons. Integrated intensity values of each signal per cell were normalized to
the mean integrated density of each signal across all the cells analyzed (see Materials and Methods). Sample size (AD patients), n = 3. Values are presented as
mean  SEM. Two-way ANOVA was used. Quantifications are summarized in the table provided. Arrow directions refer to the comparison of each normalized signal
to the same signal in the other group (in the “low miR-132” group comparisons are made to the “high miR-132” group and vice versa).
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All animal experiments were approved by the ethical committees of
KU Leuven and UZ Leuven (LA1210596). Eight-week-old males
were used in all stereotaxy protocols. Sample size was estimated in
pilot studies prior to each experimental approach.
Intracerebroventricular injections
The intracerebroventricular injections were performed as previously
described (Jimenez-Mateos et al, 2011) using the following stereo-
tactic coordinates: AP—0.1 mm, ML—1.0 mm, and DV—3.0 mm
(from the skull). For miR-132 downregulation, mice were infused
with 2–3 ll of miR-132 antagomiR (locked nucleic acid (LNA)-,
30-cholesterol-modified oligonucleotide) (Exiqon, Denmark) in artifi-
cial cerebrospinal fluid (CSF) (Harvard Apparatus, USA). Control
mice received either a scrambled LNA oligonucleotide or CSF. In
total, four injections of 0.66 nmol each were performed per animal
with 1-month intervals over a total period of 4 months. Analysis of
Figure 8. miR-132/ITPKB pathway assessment in human AD hippocampus.
Semi-quantitative PCR of miR-132 and Western blot analysis of ITPKB, phosphorylated (pERK1/2) and total ERK1/2, phosphorylated (AT8, AT270) and total TAU,
phosphorylated sphingosinekinase1 (pSphK1), BACE1, full lengthAPP (flAPP), APPCTFsand sAPPb inhumanADhippocampi (AD) compared tonon-dementedcontrol samples (ND).
Sample size, n = 39 for AD and n = 15 for ND. Values were normalized to ND and presented as mean  SEM. Student’s t-test was used.
Source data are available online for this figure.
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antagomiR-132-injected animals was performed at 6 months of age.
For miR-132 overexpression, mice received either a miR-132 mimic
or a negative control oligonucleotide (Dharmacon, GE Healthcare,
Belgium) in a mix with lipofectamine 2000 (at a 1:1 volume ratio)
(Thermo Fischer Scientific, Belgium). Injections of 150 pmol oligo
each were performed once a week for 1 month in total. Analysis of
miR-132 mimic-injected animals was carried out at 3 months of age.
For in vivo ITPKB downregulation, 11-week-old mice received either
an siRNA against ITPKB (Accell mouse SMARTpool ITPKB siRNA,
Dharmacon, GE Healthcare, Belgium) or a control oligonucleotide (2
injections of 1 lg each with 4 days interval at a 1:1 volume ratio in
lipofectamine) and sacrificed at 3 months of age. Randomization of
injectates was employed for all injection sessions, and animals were
randomly allocated to each treatment.
RNA isolation, reverse transcription, and real-time PCR
For RNA analysis, hippocampi were processed using the miRVana
Paris Kit (Life Technologies, Belgium) according to the manufac-
turer’s instructions. Briefly, tissue was homogenized (or cells were
lysed) in 300 ll cell disruption buffer supplemented with protease
and phosphatase inhibitors. Following denaturation, addition of acid
phenol:chloroform, incubation, and centrifugation, 1.25 volumes of
ethanol 100% were added to the aqueous phase. The samples were
then loaded on miRVana spin columns and processed according to
the manufacturer’s instructions. Reverse transcription of 200 ng
(mRNA) or 100 ng (miRNA) RNA was performed using the Super-
script II reverse transcriptase (Invitrogen, Life Technologies Europe,
Belgium) for protein-coding transcripts and the Universal cDNA
synthesis kit (Exiqon, Denmark) for miRNAs. Real-time semi-quan-
titative PCR was performed using the LightCycler 480 Sybr Green
(Roche Diagnostics, Belgium) for coding transcripts and the Sybr
Green mastermix and LNA PCR primers (Exiqon, Denmark) for
miRNAs. The primer sequences can be found in Appendix Table S1.
Primers. Cp (crossing points) were determined by using the second
derivative method. Fold changes were calculated with the DDCt
method (Livak & Schmittgen, 2001).
Western blotting
For protein analysis, tissue was homogenized (or cells were lysed)
in 300 ll cell disruption buffer as described above. Following
centrifugation, the supernatants were diluted in 1× SDS–PAGE load-
ing buffer containing 5% b-mercaptoethanol, boiled for 5 min at
96°C and centrifuged briefly. About 15 lg (mouse), 15 lg (cells), or
30 lg (human) of protein were finally electrophoresed on NuPAGE
10% Bis-Tris gels (Invitrogen, Life Technologies, Belgium). Follow-
ing electrotransfer, the nitrocellulose membranes were blocked in
blocking solution (5% milk powder in TBS-Tween 0.1%) and then
incubated with primary antibodies in blocking solution overnight.
Blots were incubated with the appropriate secondary antibody in
blocking solution for 1 h at room temperature and then developed
using chemiluminescence (Perkin Elmer, USA).
Fluorescent in situ hybridization and immunofluorescence
The in situ hybridization protocol was adapted from Silahtaroglu
et al (2007); Papadopoulou et al (2015). Briefly, 20 lm (mouse)- or
18 lm (human)-thick brain sagittal cryosections were postfixed in
ice-cold PFA 4% for 15 min, acetylated for 1 min, and prehy-
bridized in 50% formamide, 5×SSC and 500 lg/ml yeast t-RNA
(prehybridization buffer) for 1 h at 60°C. Hybridization was
performed with 42 nM of miR probe or scrambled negative control
(50-fluorescein, LNA, 20-OMe oligonucleotides) (Ribotask, Denmark)
in prehybridization buffer for 1 h at 70°C. Following posthybridiza-
tion washes in 0.2× SSC (70°C), 0.5× SSC (70°C), 2× SSC (room
temperature) and incubation in 3% H2O2 for 7 min, sections were
incubated in 0.5% BSA and 0.5% blocking reagent (Roche Diagnos-
tics, Belgium) (blocking solution 1). Finally, sections were probed
with an antifluorescein HRP-conjugated antibody (Roche Diagnos-
tics, Belgium) in blocking solution 1 and signals were developed in
TSA Plus Fluorescein reagent (Perkin Elmer, USA). For immunofluo-
rescence, samples were subsequently boiled in 10 mM sodium
citrate, 0.05% Tween-20, pH 6.0 for antigen retrieval, incubated in
2% normal goat serum in 0.5% TBS-Triton X-100 for 1 h (blocking
solution 2), probed with the primary antibodies in blocking solution
2 at 4°C overnight and with the appropriate secondary antibodies
for 2 h at room temperature. Finally, sections were incubated in
DAPI (Sigma-Aldrich, Belgium) and mounted in Mowiol.
Image acquisition and quantification
Images (z-stacks) were acquired using a Nikon A1R Eclipse Ti
confocal microscope. The FIJI software was employed for image
processing and quantification. In all quantifications, four sections
per sample were used with 100 lm distance between each two
sections and average values for each sample were calculated. For
amyloid burden, a region of interest was manually drawn around
each plaque and the total area occupied by plaques in hippocampus
or cortex was calculated per sample. The mean of the total area in
scramble-injected mice was set to 100, and all values were normal-
ized to 100%. For miR-132 and miR-124 total signal quantification
in human prefrontal cortex, integrated density of miR staining in
grey matter was calculated. The mean of the integrated density in
ND samples was set to 100, and all values were normalized to
100%. For single-cell colocalization analysis of miR-132, ITPKB,
and pTAU, the mean integrated density for each of the three signals
(miR-132, ITPKB, and AT8) across all the cells analyzed (435 cells)
was set to 100. The integrated intensity of each of the three signals
for each cell was then normalized against the appropriate mean to
100%. Eventually cells were grouped together into two separate
groups based on the miR-132 normalized intensity (high or low).
The cell populations analyzed spread equally across the three AD
PFC samples. All image quantifications were performed in a single-
blind manner.
Antibodies
Western blotting: mouse anti-CDK5 (1:1,000, sc-6247, Santa Cruz,
USA); rabbit anti-GSK3b (9315), rabbit anti-ERK1/2 (9102), rabbit
anti-pERK (9101s), rabbit anti-BACE1 (1:1,000, s5606, Cell Signaling,
USA); mouse TAU-5 (anti-total TAU) (1:1,000, 577801, Calbiochem,
Merch Chemicals, Belgium); mouse AT8 (MN1020), AT100
(MN1060), AT180 (MN1040), AT270 (MN1050) (1:500, Pharmingen,
BD Biosciences, Belgium); rabbit anti-ITPKB (1:500, 12816-1-AP,
Proteintech, Germany); rabbit B63 (anti-flAPP, anti-CTFs) (De
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Strooper et al, 1993); rabbit anti-sAPPb wild-type (1:500, 813401,
Covance BioLegend, USA); mouse anti-sAPPb Swe (1:250, 10321, IBL,
Germany); and anti-pSphK (1:500, SP1641, ECM Biosciences, USA).
Immunofluorescence: mouse AT8 (1:100, Cell Signaling, USA);
rabbit anti-ITPKB (1:50, Proteintech, Germany); and mouse 6E10
(amyloid staining) (1:150, 803002, BioLegend, USA).
Cell culture and transfections
For miR-132 downregulation, a miR-132 antisense hairpin inhibitor
was used (GE Healthcare, Belgium) to transfect HEK293-APPswe
using lipofectamine. Control transfections were performed using a
negative hairpin oligonucleotide (GE Healthcare, Belgium). For
ITPKB knockdown, a 27-mer siRNA duplex against human ITPKB or
a scrambled negative control were used (Origene, USA) to transfect
HEK293-APPswe using lipofectamine. Briefly, cells were seeded on
12-well plates at a cell density of 250,000 cells per well. Twenty-four
hours after seeding, cells were transfected and finally harvested
72 h thereafter.
Correlation analysis
To correlate the expression of hsa-miR-132-3p to the expression of its
predicted targets in the human prefrontal cortex, the normalized
miRNA deep sequencing data were obtained from Lau et al (2013)
and the normalized mRNA microarray data from Bossers et al
(2010), both of which were performed on the prefrontal cortex of the
same patient cohort from the Netherlands Brain Bank (Amsterdam,
Netherlands). The data for the six Braak 0-I and six Braak V-VI
patients were derived from the full normalized mRNA microarray
dataset. Pearson’s correlation coefficient and accompanying P-values
and Benjamini–Hochberg-corrected P-values were calculated for the
expression of hsa-miR-132-3p versus all detected mRNAs. A total of
960 transcripts were mapped to the mRNA profiling dataset out of a
total of 1332 initially predicted (Targetscan 7.0) miR-132 targets.
Luciferase assay
The 30UTRs were obtained by Gen9, Inc., USA. Subcloning into the
psiCHECK plasmid, transfection into wild-type HEK293 cells, and
luciferase assay were performed as previously described (Salta et al,
2014).
Ab extraction and ELISA
For Ab isolation and quantification in hippocampi, the three-step Ab
extraction protocol was adapted from Shankar et al (2011). Briefly,
TBS extracts were prepared by mechanical homogenization of tissue
in TBS supplemented with protease and phosphatase inhibitors and
subsequent centrifugation at 88,000 g in a TLA 100.4 rotor on a
Beckman for 1 h at 4°C. TBS-Triton X-100 extracts were obtained by
rehomogenizing the pellets from the previous step in TBS with 1%
Triton X-100, followed by ultracentrifugation as before. Finally,
rehomogenization of the previous pellet in 88% formic acid, sonica-
tion, overnight incubation at 4°C, and neutralization in non-buffered
Tris 1 M yielded the formic acid extract. For Ab quantification
in vitro, HEK293-APPswe (kind gift from Christian Haass) were
grown on poly-l-lysine plates in DMEM/F12 with 10% FBS for 48 h
following transfection. Medium was replaced with DMEM/F12 with
1% FBS, and cells (for protein and RNA isolation) and medium (for
Ab quantification) were collected 24 h thereafter. Ab ELISA
measurements were performed as previously described (Thathiah
et al, 2013). Values were normalized to extract protein concentra-
tion (for TBS extracts) or cell protein concentration (for HEK293-
APPswe).
Human samples
Hippocampal tissue samples were obtained from the London
Neurodegenerative Diseases Brain Bank. These samples were patho-
logically confirmed but not further categorized according to Braak
stage (Thathiah et al, 2013). Prefrontal cortex tissue blocks were
obtained from the Banner Sun Health Research institute (Arizona,
USA). All brain samples were collected according to legislation and
ethical boards of the respective brain banks. The human study was
evaluated and approved by the ethical committees of Leuven
University and UZ Leuven (Thathiah et al, 2013). Protein extracts
were prepared in 2% SDS supplemented with protease and phos-
phatase inhibitors.
Expanded View for this article is available online.
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The paper explained
Problem
Several microRNAs are deregulated in AD brain, suggesting their func-
tional interrelationship to AD pathology. More specifically, microRNA-
132 (miR-132), a potent neuroprotective molecule, is robustly down-
regulated early on in AD patients. We address here the functional
implications of miR-132 loss in AD brain and investigate the potential
of using miR-132 in the clinic in the future.
Results
We show that miR-132 is a potent early regulator of both Ab and TAU
pathology via its target ITPKB, which further activates ERK1/2 leading
to increased BACE1 activity and TAU phosphorylation. Lowering miR-
132 in the brain of an AD mouse model aggravates both arms of the
pathology, while boosting miR-132 levels ameliorates both amyloido-
sis and TAU hyperphosphorylation. Similar changes are observed in
human AD brain, where we observed decreasing miR-132, increasing
ITPKB and phospho-ERK1/2, enhanced BACE1 processing of APP, and
TAU hyperphosphorylation. The data provide functional evidence for
the importance of the previously reported downregulation of miR-132
in AD brain.
Impact
Identifying novel mechanisms that contribute to the preclinical phases
of AD pathology is of critical importance for early intervention. Restor-
ing miR-132 levels in human diseased brain might represent a novel
therapeutic target in AD.
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